About

Corporate finance and biotech are wary of each other.

On one side: predictability, control, traceability. On the other: high risk, long cycles, lumpy spending. Redmontis was designed at that intersection.

Mission

Give biotech executives back control of their cash, and the time that comes with it.

A biotech CEO juggles science, funding and a demanding board. Financial steering shouldn't cost them their days or hinge on a spreadsheet only they understand. They need to see their runway at any moment and respond fast, without turning into an analyst.

Generalist financial tools ignore clinical milestones and R&D disbursements. Spreadsheets can't take the load. Redmontis fills that gap with a single, traceable and defensible source of data, shared between the executive and their finance team.

Origin

Born in the field, not on a slide.

Redmontis didn't start as a software idea, but as an Excel model built by the founder of Redmontis, used under real-world biotech management conditions and refined over 5 years, board after board, raise after raise. Right where spreadsheets break the moment a trial slips or a grant moves three months out.

Biotech executives and CFOs used it for several months with their own data to improve its responsiveness and relevance before it became a SaaS. They observed its use and value under real-world conditions. Every screen grew out of that use, not from abstract functional logic.

From that battle-tested model, the Redmontis solution was born.

The founder

A tool written by the person who needed it.

Christophe Hubert

Founder & CEO · Redmontis

Former biotech CEO, expert in FP&A and financial strategy for biotechs. He lived through the cash decisions that make or break a biotech from the inside, then turned the tool he used into a product.

Redmontis did not come out of a market study: it is his own steering model, kept under real-world conditions, that his peers asked him to open up.

Running biotechsFinancial steering lived from the executive's chair, not from a consultancy.

FP&A and funding strategyRunway, fundraising scenarios, use of proceeds, board reporting.

5 years in the fieldA model refined board after board, raise after raise, on real data.

Tested by his peersUsed for several months by biotech executives and CFOs before it became a product.

contact@redmontis.com LinkedIn

Ecosystem

Recognised by the sector.

Associate member

France Biotech

Partner

Lyonbiopôle accelerator

Speaker

Financial steering, Lyonbiopôle (December 2026)

Speaker

OncoEntrepreneur programme, Paris Saclay Cancer Cluster (May 2027)

Vision

Become the standard financial infrastructure for biotech.

What the Bloomberg terminal is to capital markets, Redmontis aims to be to biotech financial decision-making.

Precision above all

Defensible, traceable figures that stand up to a board or an auditor.

Designed, not adapted

Built natively for the constraints of biotech, not a generalist tool dressed up.

Institutional restraint

The voice of a senior CFO who knows their subject and doesn't have to sell themselves.

Target

Biotech CEOs and CFOs

Sector

Early-stage biotech, from Seed to Series C

Scope

Runway, scenarios, Use of Proceeds, CIR

Who it's for

First for the executive, then for their finance team.

The CEO sees their runway and decides without opening a file
The CFO or controller works on the same data
The board reads clear, consistent reporting
Not an accounting ERP, not a clinical data tool

Let's talk about your financial steering.

Biotech executive or finance lead, let's see how Redmontis fits into your day-to-day.